Drug Profile

Ivarmacitinib - Arcutis Biotherapeutics/Jiangsu HengRui Medicine

Alternative Names: ARQ-252; ARQ-255; Ivarmacitinib sulfate; SHR-0302

Latest Information Update: 18 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Jiangsu Hengrui Medicine Co.
Developer Arcutis Biotherapeutics; Jiangsu Hengrui Medicine Co.; Reistone Biopharma
Class 2 ring heterocyclic compounds; Amides; Amines; Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Cyclopentanes; Heterocyclic bicyclo compounds; Methyl ethers; Pyrimidines; Pyrroles; Pyrrolidines; Skin disorder therapies; Small molecules; Sulfates; Thiadiazoles
Mechanism of Action Janus kinase 1 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Registered Ankylosing spondylitis
Preregistration Alopecia areata; Atopic dermatitis; Rheumatoid arthritis
Phase III Non-radiographic axial spondyloarthritis; Psoriatic arthritis; Ulcerative colitis
Phase II/III Vitiligo
Phase II Crohn's disease; Peripheral T-cell lymphoma
Phase I Graft-versus-host disease
Preclinical Eczema

13 Apr 2025 Chunxia Su plans a phase II trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Inoperable/unresectable, Late stage disease, Metastatic disease, Second-line therapy or greater) (NCT06925048)
25 Mar 2025 Chemical structure information updated.
24 Mar 2025 Preregistration for Atopic dermatitis in Canada (PO), before March 2025 (Jiangsu HengRui Medicine pipeline, March 2025)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com